Rucaparib

Search with Google Search with Bing

Information
Drug Name
Rucaparib
Description
Entry(CIViC)
19
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
ovarian cancer BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Somatic 4 27908594 Detail
ovarian cancer BRCA1 p.? (p.?)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.? (p.?)
( ENST00000461574.2, ENST00000357654.9, ENST00000591534.5, ENST00000352993.7, ENST00000477152.6, ENST00000468300.5, ENST00000473961.6, ENST00000591849.5, ENST00000634433.2, ENST00000470026.6, ENST00000713676.1, ENST00000497488.2, ENST00000471181.7, ENST00000493919.6, ENST00000644555.2, ENST00000493795.5, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000491747.6, ENST00000618469.2, ENST00000586385.5, ENST00000644379.2 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.? (p.?)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.? (p.?)
( ENST00000484087.6, ENST00000494123.6, ENST00000478531.6, ENST00000493795.5, ENST00000473961.6, ENST00000644555.2, ENST00000468300.5, ENST00000477152.6, ENST00000352993.7, ENST00000493919.6, ENST00000591534.5, ENST00000471181.7, ENST00000497488.2, ENST00000357654.9, ENST00000461574.2, ENST00000713676.1, ENST00000644379.2, ENST00000586385.5, ENST00000618469.2, ENST00000470026.6, ENST00000491747.6, ENST00000634433.2, ENST00000591849.5, ENST00000489037.2, ENST00000700182.1, ENST00000476777.6 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Cys61Gly (p.C61G)
( ENST00000489037.2, ENST00000476777.6, ENST00000700182.1, ENST00000470026.6, ENST00000491747.6, ENST00000586385.5, ENST00000618469.2, ENST00000713676.1, ENST00000644379.2, ENST00000591849.5, ENST00000634433.2, ENST00000493919.6, ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000471181.7, ENST00000497488.2, ENST00000591534.5, ENST00000493795.5, ENST00000484087.6, ENST00000494123.6, ENST00000478531.6, ENST00000477152.6, ENST00000473961.6, ENST00000644555.2, ENST00000468300.5 ) BRCA1 p.Cys61Gly (p.C61G)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Cys64Tyr (p.C64Y)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Cys64Tyr (p.C64Y)
( ENST00000471181.7, ENST00000478531.6, ENST00000591534.5, ENST00000586385.5, ENST00000476777.6, ENST00000352993.7, ENST00000491747.6, ENST00000468300.5, ENST00000470026.6, ENST00000497488.2, ENST00000477152.6, ENST00000493919.6, ENST00000484087.6, ENST00000489037.2, ENST00000357654.9, ENST00000493795.5, ENST00000473961.6, ENST00000494123.6, ENST00000591849.5, ENST00000461574.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Arg71Gly (p.R71G)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg71Gly (p.R71G)
( ENST00000497488.2, ENST00000471181.7, ENST00000591534.5, ENST00000461574.2, ENST00000357654.9, ENST00000352993.7, ENST00000493919.6, ENST00000468300.5, ENST00000644555.2, ENST00000473961.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000493795.5, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000634433.2, ENST00000591849.5, ENST00000644379.2, ENST00000713676.1, ENST00000491747.6, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Arg71Lys (p.R71K)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg71Lys (p.R71K)
( ENST00000489037.2, ENST00000713676.1, ENST00000491747.6, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5, ENST00000497488.2, ENST00000471181.7, ENST00000357654.9, ENST00000644555.2, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000476777.6, ENST00000700182.1, ENST00000634433.2, ENST00000591849.5, ENST00000644379.2, ENST00000591534.5, ENST00000461574.2, ENST00000352993.7, ENST00000493919.6, ENST00000468300.5, ENST00000473961.6, ENST00000493795.5 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Arg1516Met (p.R1516M)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg1516Met (p.R1516M)
( ENST00000352993.7, ENST00000493919.6, ENST00000586385.5, ENST00000461574.2, ENST00000357654.9, ENST00000471181.7, ENST00000478531.6, ENST00000591534.5, ENST00000468300.5, ENST00000493795.5, ENST00000591849.5, ENST00000484087.6, ENST00000491747.6, ENST00000470026.6, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000489037.2, ENST00000494123.6, ENST00000497488.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Glu1580Lys (p.E1580K)
( ENST00000634433.2, ENST00000591849.5, ENST00000644379.2, ENST00000713676.1, ENST00000491747.6, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000468300.5, ENST00000644555.2, ENST00000473961.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000493795.5, ENST00000497488.2, ENST00000471181.7, ENST00000591534.5, ENST00000461574.2, ENST00000357654.9, ENST00000352993.7, ENST00000493919.6 ) BRCA1 p.Glu1580Lys (p.E1580K)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Asp1713Asn (p.D1713N)
( ENST00000471181.7, ENST00000497488.2, ENST00000484087.6, ENST00000713676.1, ENST00000591849.5, ENST00000352993.7, ENST00000493919.6, ENST00000591534.5, ENST00000357654.9, ENST00000461574.2, ENST00000494123.6, ENST00000478531.6, ENST00000493795.5, ENST00000473961.6, ENST00000644555.2, ENST00000468300.5, ENST00000477152.6, ENST00000489037.2, ENST00000476777.6, ENST00000644379.2, ENST00000470026.6, ENST00000491747.6, ENST00000586385.5, ENST00000618469.2, ENST00000634433.2 ) BRCA1 p.Asp1713Asn (p.D1713N)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Arg1443Ter (p.R1443*)
( ENST00000591849.5, ENST00000471181.7, ENST00000478531.6, ENST00000493795.5, ENST00000586385.5, ENST00000461574.2, ENST00000491747.6, ENST00000484087.6, ENST00000468300.5, ENST00000591534.5, ENST00000493919.6, ENST00000352993.7, ENST00000357654.9, ENST00000470026.6, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000489037.2, ENST00000494123.6, ENST00000497488.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg1443Ter (p.R1443*)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA1 p.Gln1488Ter (p.Q1488*)
( ENST00000497488.2, ENST00000591534.5, ENST00000357654.9, ENST00000493919.6, ENST00000468300.5, ENST00000473961.6, ENST00000477152.6, ENST00000484087.6, ENST00000493795.5, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000634433.2, ENST00000713676.1, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5, ENST00000471181.7, ENST00000461574.2, ENST00000352993.7, ENST00000644555.2, ENST00000478531.6, ENST00000494123.6, ENST00000591849.5, ENST00000644379.2, ENST00000491747.6 ) BRCA1 p.Gln1488Ter (p.Q1488*)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 p.? (p.?)
( ENST00000713680.1, ENST00000713678.1, ENST00000700202.2, ENST00000380152.8, ENST00000544455.6, ENST00000530893.7 ) BRCA2 p.? (p.?)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 p.? (p.?)
( ENST00000713680.1, ENST00000713678.1, ENST00000700202.2, ENST00000380152.8, ENST00000544455.6, ENST00000530893.7 ) BRCA2 p.? (p.?)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 p.Val159Met (p.V159M)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 p.Val159Met (p.V159M)
( ENST00000544455.6, ENST00000380152.8, ENST00000530893.7, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 c.631+1G>C
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 c.631+1G>C
( ENST00000700202.2, ENST00000713680.1, ENST00000713678.1, ENST00000530893.7, ENST00000380152.8, ENST00000544455.6 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 c.631+1G>A
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 c.631+1G>A
( ENST00000713678.1, ENST00000713680.1, ENST00000700202.2, ENST00000530893.7, ENST00000380152.8, ENST00000544455.6 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 p.Arg2336Pro (p.R2336P)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 p.Arg2336Pro (p.R2336P)
( ENST00000713680.1, ENST00000713678.1, ENST00000700202.2, ENST00000544455.6, ENST00000380152.8, ENST00000530893.7 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
ovarian cancer BRCA2 p.Arg2336His (p.R2336H)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 p.Arg2336His (p.R2336H)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		C Predictive Supports Sensitivity/Response Somatic 27908594 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A phase 2 trial on patients with relapsed, platinu... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.? (p.?)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.? (p.?)
( ENST00000461574.2, ENST00000357654.9, ENST00000591534.5, ENST00000352993.7, ENST00000477152.6, ENST00000468300.5, ENST00000473961.6, ENST00000591849.5, ENST00000634433.2, ENST00000470026.6, ENST00000713676.1, ENST00000497488.2, ENST00000471181.7, ENST00000493919.6, ENST00000644555.2, ENST00000493795.5, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000491747.6, ENST00000618469.2, ENST00000586385.5, ENST00000644379.2 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.? (p.?)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.? (p.?)
( ENST00000484087.6, ENST00000494123.6, ENST00000478531.6, ENST00000493795.5, ENST00000473961.6, ENST00000644555.2, ENST00000468300.5, ENST00000477152.6, ENST00000352993.7, ENST00000493919.6, ENST00000591534.5, ENST00000471181.7, ENST00000497488.2, ENST00000357654.9, ENST00000461574.2, ENST00000713676.1, ENST00000644379.2, ENST00000586385.5, ENST00000618469.2, ENST00000470026.6, ENST00000491747.6, ENST00000634433.2, ENST00000591849.5, ENST00000489037.2, ENST00000700182.1, ENST00000476777.6 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Cys61Gly (p.C61G)
( ENST00000489037.2, ENST00000476777.6, ENST00000700182.1, ENST00000470026.6, ENST00000491747.6, ENST00000586385.5, ENST00000618469.2, ENST00000713676.1, ENST00000644379.2, ENST00000591849.5, ENST00000634433.2, ENST00000493919.6, ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000471181.7, ENST00000497488.2, ENST00000591534.5, ENST00000493795.5, ENST00000484087.6, ENST00000494123.6, ENST00000478531.6, ENST00000477152.6, ENST00000473961.6, ENST00000644555.2, ENST00000468300.5 ) BRCA1 p.Cys61Gly (p.C61G)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Cys64Tyr (p.C64Y)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Cys64Tyr (p.C64Y)
( ENST00000471181.7, ENST00000478531.6, ENST00000591534.5, ENST00000586385.5, ENST00000476777.6, ENST00000352993.7, ENST00000491747.6, ENST00000468300.5, ENST00000470026.6, ENST00000497488.2, ENST00000477152.6, ENST00000493919.6, ENST00000484087.6, ENST00000489037.2, ENST00000357654.9, ENST00000493795.5, ENST00000473961.6, ENST00000494123.6, ENST00000591849.5, ENST00000461574.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Arg71Gly (p.R71G)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg71Gly (p.R71G)
( ENST00000497488.2, ENST00000471181.7, ENST00000591534.5, ENST00000461574.2, ENST00000357654.9, ENST00000352993.7, ENST00000493919.6, ENST00000468300.5, ENST00000644555.2, ENST00000473961.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000493795.5, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000634433.2, ENST00000591849.5, ENST00000644379.2, ENST00000713676.1, ENST00000491747.6, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Arg71Lys (p.R71K)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg71Lys (p.R71K)
( ENST00000489037.2, ENST00000713676.1, ENST00000491747.6, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5, ENST00000497488.2, ENST00000471181.7, ENST00000357654.9, ENST00000644555.2, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000476777.6, ENST00000700182.1, ENST00000634433.2, ENST00000591849.5, ENST00000644379.2, ENST00000591534.5, ENST00000461574.2, ENST00000352993.7, ENST00000493919.6, ENST00000468300.5, ENST00000473961.6, ENST00000493795.5 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Arg1516Met (p.R1516M)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg1516Met (p.R1516M)
( ENST00000352993.7, ENST00000493919.6, ENST00000586385.5, ENST00000461574.2, ENST00000357654.9, ENST00000471181.7, ENST00000478531.6, ENST00000591534.5, ENST00000468300.5, ENST00000493795.5, ENST00000591849.5, ENST00000484087.6, ENST00000491747.6, ENST00000470026.6, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000489037.2, ENST00000494123.6, ENST00000497488.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Glu1580Lys (p.E1580K)
( ENST00000634433.2, ENST00000591849.5, ENST00000644379.2, ENST00000713676.1, ENST00000491747.6, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000468300.5, ENST00000644555.2, ENST00000473961.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000494123.6, ENST00000493795.5, ENST00000497488.2, ENST00000471181.7, ENST00000591534.5, ENST00000461574.2, ENST00000357654.9, ENST00000352993.7, ENST00000493919.6 ) BRCA1 p.Glu1580Lys (p.E1580K)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Asp1713Asn (p.D1713N)
( ENST00000471181.7, ENST00000497488.2, ENST00000484087.6, ENST00000713676.1, ENST00000591849.5, ENST00000352993.7, ENST00000493919.6, ENST00000591534.5, ENST00000357654.9, ENST00000461574.2, ENST00000494123.6, ENST00000478531.6, ENST00000493795.5, ENST00000473961.6, ENST00000644555.2, ENST00000468300.5, ENST00000477152.6, ENST00000489037.2, ENST00000476777.6, ENST00000644379.2, ENST00000470026.6, ENST00000491747.6, ENST00000586385.5, ENST00000618469.2, ENST00000634433.2 ) BRCA1 p.Asp1713Asn (p.D1713N)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Arg1443Ter (p.R1443*)
( ENST00000591849.5, ENST00000471181.7, ENST00000478531.6, ENST00000493795.5, ENST00000586385.5, ENST00000461574.2, ENST00000491747.6, ENST00000484087.6, ENST00000468300.5, ENST00000591534.5, ENST00000493919.6, ENST00000352993.7, ENST00000357654.9, ENST00000470026.6, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000489037.2, ENST00000494123.6, ENST00000497488.2, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) BRCA1 p.Arg1443Ter (p.R1443*)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA1 BRCA1 p.Gln1488Ter (p.Q1488*)
( ENST00000497488.2, ENST00000591534.5, ENST00000357654.9, ENST00000493919.6, ENST00000468300.5, ENST00000473961.6, ENST00000477152.6, ENST00000484087.6, ENST00000493795.5, ENST00000476777.6, ENST00000700182.1, ENST00000489037.2, ENST00000634433.2, ENST00000713676.1, ENST00000470026.6, ENST00000618469.2, ENST00000586385.5, ENST00000471181.7, ENST00000461574.2, ENST00000352993.7, ENST00000644555.2, ENST00000478531.6, ENST00000494123.6, ENST00000591849.5, ENST00000644379.2, ENST00000491747.6 ) BRCA1 p.Gln1488Ter (p.Q1488*)
( ENST00000352993.7, ENST00000357654.9, ENST00000461574.2, ENST00000468300.5, ENST00000470026.6, ENST00000471181.7, ENST00000473961.6, ENST00000476777.6, ENST00000477152.6, ENST00000478531.6, ENST00000484087.6, ENST00000489037.2, ENST00000491747.6, ENST00000493795.5, ENST00000493919.6, ENST00000494123.6, ENST00000497488.2, ENST00000586385.5, ENST00000591534.5, ENST00000591849.5, ENST00000618469.2, ENST00000634433.2, ENST00000644379.2, ENST00000644555.2, ENST00000700182.1, ENST00000713676.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 p.? (p.?)
( ENST00000713680.1, ENST00000713678.1, ENST00000700202.2, ENST00000380152.8, ENST00000544455.6, ENST00000530893.7 ) BRCA2 p.? (p.?)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 p.? (p.?)
( ENST00000713680.1, ENST00000713678.1, ENST00000700202.2, ENST00000380152.8, ENST00000544455.6, ENST00000530893.7 ) BRCA2 p.? (p.?)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 p.Val159Met (p.V159M)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 p.Val159Met (p.V159M)
( ENST00000544455.6, ENST00000380152.8, ENST00000530893.7, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 c.631+1G>C
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 c.631+1G>C
( ENST00000700202.2, ENST00000713680.1, ENST00000713678.1, ENST00000530893.7, ENST00000380152.8, ENST00000544455.6 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 c.631+1G>A
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 c.631+1G>A
( ENST00000713678.1, ENST00000713680.1, ENST00000700202.2, ENST00000530893.7, ENST00000380152.8, ENST00000544455.6 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 p.Arg2336Pro (p.R2336P)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 p.Arg2336Pro (p.R2336P)
( ENST00000713680.1, ENST00000713678.1, ENST00000700202.2, ENST00000544455.6, ENST00000380152.8, ENST00000530893.7 ) 		Sensitivity true CIViC Evidence detail
In a phase 2 study of 206 recurrent, platinum-sens... BRCA2 BRCA2 p.Arg2336His (p.R2336H)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) BRCA2 p.Arg2336His (p.R2336H)
( ENST00000380152.8, ENST00000530893.7, ENST00000544455.6, ENST00000700202.2, ENST00000713678.1, ENST00000713680.1 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03338790 Active, not recruiting Phase 2 An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer December 19, 2017 September 15, 2024
NCT03995017 Active, not recruiting Phase 1/Phase 2 Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma January 9, 2020 December 2024
NCT03413995 Active, not recruiting Phase 2 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations September 10, 2018 September 2024
NCT03442556 Active, not recruiting Phase 2 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency August 24, 2018 May 15, 2025
NCT03911453 Active, not recruiting Early Phase 1 Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors April 19, 2019 November 30, 2024
NCT04253262 Active, not recruiting Phase 1/Phase 2 A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer April 3, 2020 January 2027
NCT02975934 Active, not recruiting Phase 3 A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency June 13, 2017 December 2024
NCT03522246 Active, not recruiting Phase 3 A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy May 14, 2018 December 30, 2030
NCT03845296 Active, not recruiting Phase 2 Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) April 16, 2019 July 1, 2024
NCT03542175 Active, not recruiting Phase 1 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy May 23, 2018 July 25, 2024
NCT03559049 Active, not recruiting Phase 1/Phase 2 Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer December 24, 2018 July 2027
NCT03654833 Active, not recruiting Phase 2 Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma January 28, 2019 October 31, 2023
NCT03617679 Active, not recruiting Phase 2 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer March 6, 2019 September 2024
NCT03639935 Active, not recruiting Phase 2 Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy March 28, 2019 February 2025
NCT02873962 Active, not recruiting Phase 2 A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib November 10, 2016 July 2026
NCT04227522 Active, not recruiting Phase 3 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients June 8, 2020 January 2025
NCT04209595 Active, not recruiting Phase 1/Phase 2 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers April 8, 2020 December 31, 2024
NCT04624178 Active, not recruiting Phase 2 A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma November 5, 2020 November 5, 2024
NCT03337087 Active, not recruiting Phase 1/Phase 2 Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer November 2, 2018 August 9, 2025
NCT03954366 Completed Phase 1 Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives April 25, 2019 June 9, 2021
NCT01482715 Completed Phase 1/Phase 2 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) November 2011 May 2019
NCT01968213 Completed Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) April 7, 2014 July 7, 2022
NCT02042378 Completed Phase 2 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation April 2014 May 2016
NCT02505048 Completed Phase 2 A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature March 2016 December 2019
NCT02740712 Completed Phase 1 Pharmacokinetic Drug-Drug Interaction Study of Rucaparib April 2016 September 2019
NCT02855944 Completed Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients March 1, 2017 September 16, 2022
NCT02935634 Completed Phase 2 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer November 29, 2016 May 11, 2022
NCT02952534 Completed Phase 2 A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency February 15, 2017 July 27, 2021
NCT02986100 Completed Phase 1 Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib November 2016 September 2018
NCT03101280 Completed Phase 1 A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer April 27, 2017 August 11, 2020
NCT03318445 Completed Phase 1 Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair January 12, 2018 March 1, 2021
NCT03476798 Completed Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium June 29, 2018 September 29, 2023
NCT03499444 Completed Phase 1 A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor February 6, 2018 April 13, 2022
NCT03694262 Completed Phase 2 The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) July 19, 2019 April 5, 2023
NCT03840200 Completed Phase 1 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. June 12, 2019 January 4, 2022
NCT01074970 Completed Phase 2 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations February 2010 December 15, 2018
NCT04179396 Completed Phase 1 Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) December 5, 2019 January 18, 2023
NCT04539327 Completed Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study July 29, 2020 July 31, 2021
NCT04676334 Completed Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib March 22, 2021 March 8, 2023
NCT04826198 Recruiting Phase 1/Phase 2 Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months October 5, 2020 October 2023
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT03462212 Recruiting Phase 1/Phase 2 Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination March 17, 2021 March 1, 2025
NCT03899155 Recruiting Phase 2 Pan Tumor Rollover Study August 9, 2019 August 25, 2029
NCT03768063 Recruiting Phase 3 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study February 28, 2019 July 5, 2028
NCT02678182 Recruiting Phase 2 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial February 2015 June 2027
NCT04276376 Suspended Phase 2 Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors April 12, 2019 April 2025
NCT03824704 Terminated Phase 2 A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) August 23, 2019 August 24, 2020
NCT03140670 Terminated Phase 2 Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy September 5, 2017 August 7, 2023
NCT03992131 Terminated Phase 1/Phase 2 A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) June 28, 2019 April 22, 2022
NCT03397394 Terminated Phase 2 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma June 1, 2018 January 15, 2020
NCT04171700 Terminated Phase 2 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes January 16, 2020 July 15, 2022
NCT03533946 Terminated Phase 2 Rucaparib in Nonmetastatic prOstAte With BRCAness May 20, 2019 January 12, 2023
NCT03572478 Terminated Phase 1/Phase 2 Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer August 14, 2018 October 1, 2020
NCT02711137 Terminated Phase 1/Phase 2 Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies May 18, 2016 February 13, 2019
NCT03795272 Withdrawn Phase 2 Rucaparib Maintenance Therapy in Advanced Cervical Cancer October 1, 2019 October 10, 2019